Pharmaceutical manufacturers, such as Pfizer, Johnson & Johnson, and Novartis, are driving digital transformation to enhance production efficiency and maintain compliance—an essential factor in ...

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month.

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe’s genomics ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services. By Michael Levenson 23andMe, the genetic ...

Acadia Pharmaceuticals (NASDAQ:ACAD) soared 28% after a court ruling in patent suit regarding its drug Nuplazid, which is used to treat Parkinson's disease. The court ruled that Aurobindo Pharma ...

The pharmaceutical industry, which is well known for its well-resourced lobbying campaigns, has a lesser-known tactic for influencing policy: bankrolling ostensibly independent nonprofit ...

Shares of Indian pharmaceutical companies plunged close to 6% on Monday after US President Donald Trump proposed sweeping price cuts on prescription drugs and pharma prices in the US, although ...

For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the ...

However, the environmental cost is huge, and the pharmaceutical industry has struggled to find a sustainable alternative. Enter the Tully Tube, a revolutionary new pill bottle made mostly from 100 ...

Ono Pharma’s U.S. arm is laying off 83 staffers at its site in Cambridge, Massachusetts. The workforce reduction is effective June 30, according to a state Worker Adjustment and Retraining ...

For the second year in a row, the pharmaceutical industry has dipped further out of favor with patient groups around the world. The industry’s reputation surged during the COVID-19 pandemic ...